Avenue Therapeutics (ATXI) Stock Price & Analysis

ATXI Stock Chart & Stats

$0.43$0.05(12.37%)

At close: Oct 30 4:00 PM EDT

Day’s Range: $0.43 - $0.43
52-Week Range: $0.15 - $0.97
Previous Close: $0.38
Volume: 16.16K
Average Volume (3M): 3,014
Market Cap: $1.41M
Enterprise Value: -$2.46M
Total Cash (Recent Filing): $1.94M
Total Debt (Recent Filing): $0
Price to Earnings (P/E): ―
Beta: 1.12
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance Sheet

The absence of debt reduces mandatory interest and repayment burdens, giving Avenue greater flexibility while it advances development programs. This lowers financial risk relative to a similarly loss-making company with leverage, although the benefit depends on preserving enough liquidity to fund operations.

Narrower Net Losses

The substantial reduction in annual losses indicates some progress in controlling the cost base and improving operating efficiency. If sustained, this trajectory could extend the company’s funding runway and reduce the scale of future capital needs as development activities continue.

Improved Cash Burn

Lower operating cash outflows than in earlier periods suggest better control of cash consumption, an important advantage for a development-stage biotechnology company. Continued improvement could preserve resources for clinical and regulatory work, even though operations remain cash-consuming today.

Bears Say

No Current Revenue

The complete absence of trailing revenue shows that Avenue currently lacks a recurring commercial base to support research, regulatory, and corporate spending. Without an approved product or dependable monetization stream, financial progress remains highly dependent on future development outcomes or external funding.

Persistent Cash Consumption

Negative operating and free cash flow means the business is not self-funding and must continue using available resources or seek external financing to sustain operations. This constrains strategic flexibility and leaves the company exposed if losses persist or development spending increases.

Shrinking Equity Cushion

The sharp reduction in equity reflects ongoing value erosion from operating losses and leaves a much thinner balance-sheet cushion against further setbacks. With only modest assets and continued cash consumption, Avenue has less capacity to absorb delays or fund development internally.

Avenue Therapeutics News

Avenue Therapeutics Licenses ATX-04 for Pompe Disease

Avenue Therapeutics ( ($ATXI) ) has issued an update. On February 23, 2026, Avenue Therapeutics announced it had entered an exclusive worldwide license agreement with Duke University covering patents and

8M ago8K ATXI

Avenue Therapeutics enters worldwide license agreement for ATX-04

Avenue Therapeutics (ATXI) announced that it has entered into an exclusive worldwide license agreement with Duke University for patents and know-how pertaining to ATX-04 in clinical development for the treatment

8M agoATXI 49Y

Avenue Therapeutics shareholders elect directors, ratify KPMG auditor

Avenue Therapeutics ( ($ATXI) ) has provided an update. At its 2025 annual meeting of stockholders held virtually on December 30, 2025, Avenue Therapeutics, Inc. shareholders elected six directors —

10M ago8K ATXI

Avenue Therapeutics Announces 2025 Annual Meeting Date

Avenue Therapeutics ( ($ATXI) ) has issued an update. Avenue Therapeutics, Inc. has announced December 30, 2025, as the date for its 2025 annual meeting of stockholders. Stockholders must submit

11M ago8K ATXI

Avenue Therapeutics Reports Improved Financials Amid Challenges

Avenue Therapeutics ( ($ATXI) ) has released its Q3 earnings. Here is a breakdown of the information Avenue Therapeutics presented to its investors. Avenue Therapeutics, Inc. is a specialty pharmaceutical

11M agoATXI 49Y

Avenue Therapeutics Sells Baergic Bio to Axsome

The latest announcement is out from Avenue Therapeutics ( ($ATXI) ). On November 5, 2025, Avenue Therapeutics and its subsidiary Baergic Bio entered into an agreement with Axsome Therapeutics for

11M ago8K ATXI

Avenue Therapeutics announces Baergic Bio acquisition by Axsome

Avenue Therapeutics (ATXI) subsidiary, Baergic Bio announced that Avenue has entered into an agreement for Baergic to be acquired by Axsome Therapeutics (AXSM), including the global rights to BAER-101, a

12M agoAZN ATXI

Axsome enters agreement to obtain exclusive global rights to AZD7325

Axsome Therapeutics (AXSM) (AZXM) entered into an agreement to obtain exclusive global rights to AZD7325, a novel oral GABAA receptor alpha subtype-selective positive allosteric modulator, licensed from AstraZeneca AB (AZN).

12M agoAZN ATXI

Avenue Therapeutics Reports Positive Earnings Amid Challenges

Avenue Therapeutics ( ($ATXI) ) has released its Q2 earnings. Here is a breakdown of the information Avenue Therapeutics presented to its investors. Avenue Therapeutics, Inc. is a specialty pharmaceutical

1y agoATXI 49Y

Avenue Therapeutics Ends License Agreement with AnnJi

An update from Avenue Therapeutics ( ($ATXI) ) is now available. On April 24, 2025, Avenue Therapeutics and AnnJi Pharmaceutical terminated their license agreement concerning the AJ201 molecule, following AnnJi’s

1y ago8K ATXI

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Lyell Immunopharma (LYEL), 807% surge in interest Immunovant (IMVT),

1y agoINO ARCT

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Annexon (ANNX), 807% surge in interest Avenue Therapeutics (ATXI),

1y agoPLX SLS

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: PMGC Holdings (ELAB), 4,788% surge in interest Avenue Therapeutics

1y agoATXI BTAI

Avenue Therapeutics files $35M mixed securities shelf

17:16 EST Avenue Therapeutics (ATXI) files $35M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks

1y agoATXI 49Y

ATXI FAQ

What was Avenue Therapeutics’s price range in the past 12 months?

Avenue Therapeutics lowest stock price was $0.15 and its highest was $0.97 in the past 12 months.

What is Avenue Therapeutics’s market cap?

Avenue Therapeutics’s market cap is $1.41M.

When is Avenue Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Avenue Therapeutics’s earnings last quarter?

Avenue Therapeutics released its earnings results on Nov 17, 2025. The company reported -$0.214 earnings per share for the quarter.

Is Avenue Therapeutics overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Avenue Therapeutics pay dividends?

Avenue Therapeutics does not currently pay dividends.

What is Avenue Therapeutics’s EPS estimate?

Avenue Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Avenue Therapeutics have?

Avenue Therapeutics has 3,294,967 shares outstanding.

What happened to Avenue Therapeutics’s price movement after its last earnings report?

Avenue Therapeutics reported an EPS of -$0.214 in its last earnings report. Following the earnings report the stock price went up 5.263%.

Which hedge fund is a major shareholder of Avenue Therapeutics?

Currently, no hedge funds are holding shares in ATXI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description